These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21204733)

  • 21. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
    Loren J; Huang Z; Laffitte BA; Molteni V
    Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver X Receptors and female reproduction: when cholesterol meets fertility!
    Lobaccaro JM; Gallot D; Lumbroso S; Mouzat K
    J Endocrinol Invest; 2013 Jan; 36(1):55-60. PubMed ID: 23211426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver X receptors: emerging therapeutic targets for Alzheimer's disease.
    Sodhi RK; Singh N
    Pharmacol Res; 2013 Jun; 72():45-51. PubMed ID: 23542729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver X receptors as regulators of metabolism.
    Korach-André M; Gustafsson JÅ
    Biomol Concepts; 2015 Jun; 6(3):177-90. PubMed ID: 25945723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LXR agonists for the treatment of atherosclerosis.
    Jaye M
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver X receptors, lipids and their reproductive secrets in the male.
    El-Hajjaji FZ; Oumeddour A; Pommier AJ; Ouvrier A; Viennois E; Dufour J; Caira F; Drevet JR; Volle DH; Baron S; Saez F; Lobaccaro JM
    Biochim Biophys Acta; 2011 Aug; 1812(8):974-81. PubMed ID: 21334438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
    Fiévet C; Staels B
    Biochem Pharmacol; 2009 Apr; 77(8):1316-27. PubMed ID: 19101522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
    Griffett K; Solt LA; El-Gendy Bel-D; Kamenecka TM; Burris TP
    ACS Chem Biol; 2013 Mar; 8(3):559-67. PubMed ID: 23237488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver x receptor signaling pathways and atherosclerosis.
    Calkin AC; Tontonoz P
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1513-8. PubMed ID: 20631351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver X receptor (LXR) and the reproductive system--a potential novel target for therapeutic intervention.
    Bełtowski J; Semczuk A
    Pharmacol Rep; 2010; 62(1):15-27. PubMed ID: 20360612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting liver X receptors in cancer therapeutics.
    Lin CY; Gustafsson JÅ
    Nat Rev Cancer; 2015 Apr; 15(4):216-24. PubMed ID: 25786697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
    Griffett K; Hayes M; Bedia-Diaz G; Appourchaux K; Sanders R; Boeckman MP; Koelblen T; Zhang J; Schulman IG; Elgendy B; Burris TP
    ACS Chem Biol; 2022 May; 17(5):1143-1154. PubMed ID: 35417135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting liver X receptors in inflammation.
    Steffensen KR; Jakobsson T; Gustafsson JÅ
    Expert Opin Ther Targets; 2013 Aug; 17(8):977-90. PubMed ID: 23738533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
    Ogawa D; Stone JF; Takata Y; Blaschke F; Chu VH; Towler DA; Law RE; Hsueh WA; Bruemmer D
    Circ Res; 2005 Apr; 96(7):e59-67. PubMed ID: 15790955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver X receptors: From pharmacology to nanoparticle-based drug delivery.
    Hua X; Wei X
    Eur J Pharmacol; 2023 Oct; 956():175953. PubMed ID: 37541371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LXR agonists: new potential therapeutic drug for neurodegenerative diseases.
    Xu P; Li D; Tang X; Bao X; Huang J; Tang Y; Yang Y; Xu H; Fan X
    Mol Neurobiol; 2013 Dec; 48(3):715-28. PubMed ID: 23625315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
    Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
    Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages.
    Töröcsik D; Szanto A; Nagy L
    Mol Aspects Med; 2009 Jun; 30(3):134-52. PubMed ID: 19248804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereo specific platelet inhibition by the natural LXR agonist 22(R)-OH-cholesterol and its fluorescence labelling with preserved bioactivity and chiral handling in macrophages.
    Schaffer S; Tandon R; Zipse H; Siess W; Schmidt A; Jamasbi J; Karshovska E; Steglich W; Lorenz R
    Biochem Pharmacol; 2013 Jul; 86(2):279-85. PubMed ID: 23665353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human ADFP gene is a direct liver-X-receptor (LXR) target gene and differentially regulated by synthetic LXR ligands.
    Kotokorpi P; Venteclef N; Ellis E; Gustafsson JA; Mode A
    Mol Pharmacol; 2010 Jan; 77(1):79-86. PubMed ID: 19843633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.